A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques

References

• Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):542–544. DOI:https://doi.org/10.1080/22221751.2020.1737580. Epub 2020/03/10. PubMed PMID: 32148172; PubMed Central PMCID: PMCPMC7144304.
   PubMed Web of Science ®Google Scholar
• Heaton PM. The covid-19 vaccine-development multiverse. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMe2025111. Epub 2020/07/15. PubMed PMID: 32663910; PubMed Central PMCID: PMCPMC7377255
   Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–488. DOI:https://doi.org/10.1016/S0140-6736(20)31605-6. PubMed PMID: 32702299.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854. DOI:https://doi.org/10.1016/S0140-6736(20)31208-3. PubMed PMID: 32450106; PubMed Central PMCID: PMCPMC7255193.
   PubMed Web of Science ®Google Scholar
• Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5:69. DOI:https://doi.org/10.1038/s41541-020-00221-3. PubMed PMID: 32793398; PubMed Central PMCID: PMCPMC7385486.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. Chadox1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020. DOI:https://doi.org/10.1038/s41586-020-2608-y. PubMed PMID: 32731258
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. DOI:https://doi.org/10.1016/S0140-6736(20)31604-4. PubMed PMID: 32702298; PubMed Central PMCID: PMCPMC7445431.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020. DOI:https://doi.org/10.1038/s41586-020-2622-0. PubMed PMID: 32756549
   Google Scholar
• Corbett KS, Edwards D, Leist SR, et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. bioRxiv. 2020. DOI:https://doi.org/10.1101/2020.06.11.145920. PubMed PMID: 32577634; PubMed Central PMCID: PMCPMC7301911 International Patent Application No. WO/2018/081318 entitled “Prefusion Coronavirus Spike Proteins and Their Use.” K.S.C., O.M.A., G.B.H., N.W., D.W., J.S.M, and B.S.G. are inventors on US Patent Application No. 62/972,886 entitled “2019-nCoV Vaccine”. R.S.B. filed an invention report for the SARS-CoV-2 MA virus (UNC ref. #18752).
   Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2024671. PubMed PMID: 32722908; PubMed Central PMCID: PMCPMC7449230.
   Google Scholar
• Jackson LA, Roberts PC, Graham BS. A SARS-CoV-2 mRNA vaccine – preliminary report reply. N Engl J Med. 2020;383(12):1191–1192. DOI:https://doi.org/10.1056/NEJMc2026616. PubMed PMID: 32813942.
   Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020. DOI:https://doi.org/10.1038/s41586-020-2639-4. PubMed PMID: 32785213.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2035389. Epub 2020/12/31. PubMed PMID: 33378609; PubMed Central PMCID: PMCPMC7787219.
   Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2034577. PubMed PMID: 33301246.
   Google Scholar
• Shin MD, Shukla S, Chung YH, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15(8):646–655. DOI:https://doi.org/10.1038/s41565-020-0737-y. PubMed PMID: 32669664.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020. DOI:https://doi.org/10.1001/jama.2020.15543. PubMed PMID: 32789505; PubMed Central PMCID: PMCPMC7426884.
   Web of Science ®Google Scholar
• Mulligan MJ. An inactivated virus candidate vaccine to prevent COVID-19. JAMA. 2020. DOI:https://doi.org/10.1001/jama.2020.15539. PubMed PMID: 32789500.
   Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. DOI:https://doi.org/10.1126/science.abc1932. PubMed PMID: 32376603; PubMed Central PMCID: PMCPMC7202686.
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang N, Zou QM. [Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(6):614–619. DOI:https://doi.org/10.3760/cma.j.cn112150-20200317-00366. PubMed PMID: 32234130.
   Google Scholar
• Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351–2356. DOI:https://doi.org/10.1080/21645515.2016.1177688. Epub 2016/06/09. PubMed PMID: 27269431; PubMed Central PMCID: PMCPMC5027702.
   PubMed Web of Science ®Google Scholar
• Bolles M, Deming D, Long K, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201–12215. DOI:https://doi.org/10.1128/JVI.06048-11. Epub 2011/09/23. PubMed PMID: 21937658; PubMed Central PMCID: PMCPMC3209347.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical trials. JAMA. 2020;324(10):951–960. DOI:https://doi.org/10.1001/jama.2020.15543. Epub 2020/08/14. PubMed PMID: 32789505; PubMed Central PMCID: PMCPMC7426884.
   PubMed Web of Science ®Google Scholar
• Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020. DOI:https://doi.org/10.1016/S1473-3099(20)30764-7. Epub 2020/10/16. PubMed PMID: 33058797; PubMed Central PMCID: PMCPMC7550103.
   PubMed Web of Science ®Google Scholar
• Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J Infect Dis. 2020. DOI:https://doi.org/10.1093/infdis/jiaa659. Epub 2020/11/04. PubMed PMID: 33140086.
   Google Scholar
• Chan PKS, Lui G, Hachim A, et al. Serologic responses in healthy adult with SARS-CoV-2 reinfection, Hong Kong, August 2020. Emerg Infect Dis. 2020;26:12. DOI:https://doi.org/10.3201/eid2612.203833. Epub 2020/10/23. PubMed PMID: 33089772.
   Web of Science ®Google Scholar
• Hollister K, Chen Y, Wang S, et al. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum Vaccin Immunother. 2014;10(7):1985–1992. DOI:https://doi.org/10.4161/hv.28659. PubMed PMID: 25424808; PubMed Central PMCID: PMCPMC4186047.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–1555. DOI:https://doi.org/10.1056/NEJMoa2024671. Epub 2020/07/30. PubMed PMID: 32722908; PubMed Central PMCID: PMCPMC7449230.
   PubMed Web of Science ®Google Scholar
• Feng L, Wang Q, Shan C, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020;11(1):4207), DOI:https://doi.org/10.1038/s41467-020-18077-5. Epub 2020/08/23. PubMed PMID: 32826924; PubMed Central PMCID: PMCPMC7442803.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–588. DOI:https://doi.org/10.1038/s41586-020-2607-z. Epub 2020/07/31. PubMed PMID: 32731257; PubMed Central PMCID: PMCPMC7581548.
   PubMed Web of Science ®Google Scholar
• Hassan AO, Kafai NM, Dmitriev IP, et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–184. DOI:https://doi.org/10.1016/j.cell.2020.08.026. Epub 2020/09/16. PubMed PMID: 32931734; PubMed Central PMCID: PMCPMC7437481.
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26(31):3947–3957. DOI:https://doi.org/10.1016/j.vaccine.2007.12.060. Epub 2008/08/30. PubMed PMID: 18724414; PubMed Central PMCID: PMCPMC3743087.
   PubMed Web of Science ®Google Scholar
• Almansour I, Chen H, Wang S, et al. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother. 2013;9(10):2049–2059. DOI:https://doi.org/10.4161/hv.25735. Epub 2013/07/26. PubMed PMID: 23884239; PubMed Central PMCID: PMCPMC3906389.
   Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–811. DOI:https://doi.org/10.1126/science.abc6284. PubMed PMID: 32434945; PubMed Central PMCID: PMCPMC7243363.
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010;28(17):2999–3007. DOI:https://doi.org/10.1016/j.vaccine.2010.02.006. Epub 2010/02/23. PubMed PMID: 20170767; PubMed Central PMCID: PMCPMC2847033.
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005;79(12):7933–7937. DOI:https://doi.org/10.1128/JVI.79.12.7933-7937.2005. Epub 2005/05/28. PubMed PMID: 15919951; PubMed Central PMCID: PMCPMC1143658.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–351. DOI:https://doi.org/10.1016/j.coi.2009.05.016. Epub 2009/06/09. . PubMed PMID: 19500964; PubMed Central PMCID: PMCPMC3743086.
   PubMed Web of Science ®Google Scholar
• Wang S, Parker C, Taaffe J, et al. Heterologous HA DNA vaccine prime–inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008;26(29–30):3626–3633. DOI:https://doi.org/10.1016/j.vaccine.2008.04.073. Epub 2008/06/10. PubMed PMID: 18538900; PubMed Central PMCID: PMCPMC2802517.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011;11(12):916–924. DOI:https://doi.org/10.1016/S1473-3099(11)70240-7. Epub 2011/10/07. PubMed PMID: 21975270; PubMed Central PMCID: PMCPMC7185472.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Hu Z, Costner P, et al. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemp Clin Trials. 2015;44:112–118. DOI:https://doi.org/10.1016/j.cct.2015.08.006. Epub 2015/08/16. PubMed PMID: 26275339; PubMed Central PMCID: PMCPMC4751067.
   Web of Science ®Google Scholar
• Wang S, Chou TH, Sakhatskyy PV, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005;79(3):1906–1910. DOI:https://doi.org/10.1128/JVI.79.3.1906-1910.2005. Epub 2005/01/15. PubMed PMID: 15650214; PubMed Central PMCID: PMCPMC544123.
   Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020. DOI:https://doi.org/10.1038/s41586-020-2599-8. Epub 2020/07/30. PubMed PMID: 32726802.
   Google Scholar
• Wang S, Taaffe J, Parker C, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006;80(23):11628–11637. DOI:https://doi.org/10.1128/JVI.01065-06. Epub 2006/09/22. PubMed PMID: 16987975; PubMed Central PMCID: PMCPMC1642598.
   Web of Science ®Google Scholar
• Wang S, Farfan-Arribas DJ, Shen S, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006;24(21):4531–4540. DOI:https://doi.org/10.1016/j.vaccine.2005.08.023. Epub 2005/09/06. PubMed PMID: 16140431.
   PubMed Web of Science ®Google Scholar
• Song HC, Seo MY, Stadler K, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol. 2004;78(19):10328–10335. DOI:https://doi.org/10.1128/JVI.78.19.10328-10335.2004. Epub 2004/09/16. PubMed PMID: 15367599; PubMed Central PMCID: PMCPMC516425.
   PubMed Web of Science ®Google Scholar
• Esposito D, Mehalko J, Drew M, et al. Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays. Protein Expr Purif. 2020;174:105686. DOI:https://doi.org/10.1016/j.pep.2020.105686. Epub 2020/06/07. PubMed PMID: 32504802; PubMed Central PMCID: PMCPMC7271859.
   Web of Science ®Google Scholar
• Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369(6510):1501–1505. DOI:https://doi.org/10.1126/science.abd0826. Epub 2020/07/25. PubMed PMID: 32703906; PubMed Central PMCID: PMCPMC7402631.
   PubMed Web of Science ®Google Scholar
• Li J, Valentin A, Kulkarni V, et al. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine. 2013;31(36):3747–3755. DOI:https://doi.org/10.1016/j.vaccine.2013.04.037. Epub 2013/04/30. PubMed PMID: 23624057.
   PubMed Web of Science ®Google Scholar
• Liu S, Wang S, Lu S. DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect. 2016;5:e33. DOI:https://doi.org/10.1038/emi.2016.27. Epub 2016/04/07. PubMed PMID: 27048742; PubMed Central PMCID: PMCPMC4855071.
   PubMed Web of Science ®Google Scholar
• Liu S, Wang S, Lu S. Using DNA immunization to elicit monoclonal antibodies in mice, rabbits, and humans. Hum Gene Ther. 2018;29(9):997–1003. DOI:https://doi.org/10.1089/hum.2018.077. Epub 2018/07/22. PubMed PMID: 30027758; PubMed Central PMCID: PMCPMC6909704.
   Web of Science ®Google Scholar
• Munson P, Liu Y, Bratt D, et al. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Hum Vaccin Immunother. 2018;14(7):1820–1831. DOI:https://doi.org/10.1080/21645515.2018.1448328. Epub 2018/04/13. PubMed PMID: 29648490; PubMed Central PMCID: PMCPMC6067903.
   PubMed Web of Science ®Google Scholar
• Fu TM, Guan L, Friedman A, et al. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol. 1999;162(7):4163–4170. Epub 1999/04/14. PubMed PMID: 10201942.
   Web of Science ®Google Scholar
• Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med. 1995;1(6):583–587. DOI:https://doi.org/10.1038/nm0695-583. Epub 1995/06/01. PubMed PMID: 7585127.
   PubMed Web of Science ®Google Scholar
• Suschak JJ, Wang S, Fitzgerald KA, et al. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015;194(2):630–636. DOI:https://doi.org/10.4049/jimmunol.1402530. PubMed PMID: 25488991; PubMed Central PMCID: PMCPMC4282968.
   PubMed Web of Science ®Google Scholar
• Wu H, Chen Y, Liu H, et al. Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice. Eur J Immunol. 2016;46(5):1152–1161. DOI:https://doi.org/10.1002/eji.201546094. PubMed PMID: 26887860; PubMed Central PMCID: PMCPMC4896226.
   PubMed Web of Science ®Google Scholar
• Hobernik D, Bros M. DNA vaccines-how far from clinical use? Int J Mol Sci. 2018;19:11. DOI:https://doi.org/10.3390/ijms19113605. Epub 2018/11/18. PubMed PMID: 30445702; PubMed Central PMCID: PMCPMC6274812.
   Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788. DOI:https://doi.org/10.1038/nrg2432. Epub 2008/09/11. PubMed PMID: 18781156; PubMed Central PMCID: PMCPMC4317294.
   PubMed Web of Science ®Google Scholar
• Xu G, Wang S, Zhuang L, et al. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera. Vaccine. 2009;27(29):3821–3830. DOI:https://doi.org/10.1016/j.vaccine.2009.04.008. Epub 2009/05/16. PubMed PMID: 19443090.
   Web of Science ®Google Scholar
• Suguitan AL J, Cheng X, Wang W, et al. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One. 2011;6(7):e21942. DOI:https://doi.org/10.1371/journal.pone.0021942. Epub 2011/07/16. PubMed PMID: 21760928; PubMed Central PMCID: PMCPMC3132217.
   Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020. DOI:https://doi.org/10.1038/s41586-020-2814-7. PubMed PMID: 32998157.
   Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. DOI:https://doi.org/10.1016/S0140-6736(20)31866-3. Epub 2020/09/09. PubMed PMID: 32896291; PubMed Central PMCID: PMCPMC7471804.
   PubMed Web of Science ®Google Scholar